title: Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk.
abstract: OBJECTIVE
  High IgA-class (but not IgG-class) Anti-Heat-shock-protein 60 antibody level is a predictor of coronary risk in dyslipidemic middle-aged men. In this paper we studied the joint effects of high Anti-Hsp60-antibody level and the classical coronary risk factors.
  
  
  METHODS
  We used nested case-control design and logistic regression analyses. The cases consisted of 233 middle-aged men with myocardial infarction or coronary death during 8.5-year follow-up in Helsinki Heart Study, a coronary primary prevention study with gemfibrozil. The controls were subjects without coronary events, matched for drug treatment and the geographical area.
  
  
  RESULTS
  The relative coronary risks (Odds Ratios (ORs); 95% confidence interval) were 1.41 (0.96-2.05) for high IgA-class Anti-Hsp60 antibody level and 1.98 (1.35-2.90) for hypertension, defined as mean arterial pressure >114 mmHg. With simultaneous occurrence of high Anti-Hsp60 antibody level and hypertension, the ORs were 2.32 (1.26-4.27) for systolic and 2.99 (1.63-5.48) for diastolic hypertension. Similar patterns of joint effects were found between high Anti-Hsp60 antibody and lipoprotein cholesterol levels as well as antibodies against oxidized low-density lipoprotein.
  
  
  CONCLUSIONS
  Our results suggest that, while high IgA-class Anti-Hsp60 antibody level predicts coronary risk, the effect is modest without simultaneous occurrence of other classical risk factors.
authors.affiliation: Department of Medicine, Hyvinkää Hospital, Hyvinkää, Finland.
authors.forename: Helena
authors.initials: H
authors.lastname: Kervinen
authors.forename: Tiina
authors.initials: T
authors.lastname: Huittinen
authors.forename: Outi
authors.initials: O
authors.lastname: Vaarala
authors.forename: Maija
authors.initials: M
authors.lastname: Leinonen
authors.forename: Pekka
authors.initials: P
authors.lastname: Saikku
authors.forename: Vesa
authors.initials: V
authors.lastname: Manninen
authors.forename: Matti
authors.initials: M
authors.lastname: Mänttäri
mesh_terms: D000906:Antibodies / Q000097:blood*; D018834:Chaperonin 60 / Q000276:immunology*; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications*; D006973:Hypertension / Q000150:complications*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007070:Immunoglobulin A / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D012307:Risk Factors
chemical_list: D000906:Antibodies; D018834:Chaperonin 60; D000960:Hypolipidemic Agents; D007070:Immunoglobulin A; D015248:Gemfibrozil